Candriam SCA’s Stemline Therapeutics, Inc. STML Stock Holding History

Candriam SCA’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-149,466	Closed	-$1.55M	–	893
2020 Q1	$1.55M	Buy	149,466 +28	+0%	+$182	0.02%	581
2019 Q4	$1.59M	Buy	149,438 +35,438	+31%	+$352K	0.02%	598
2019 Q3	$1.19M	Buy	114,000 +34,000	+43%	+$445K	0.02%	578
2019 Q2	$1.22M	Buy	+80,000	New	+$1.16M	0.02%	614
2017 Q1	–	Sell	-244,000	Closed	-$2.61M	–	716
2016 Q4	$2.61M	Sell	244,000 -13,000	-5%	-$157K	0.06%	316
2016 Q3	$2.78M	Buy	+257,000	New	+$2.09M	0.07%	294

Candriam SCA's STML Position: Q2 2020 in Review

Candriam SCA sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 149,466 shares — an estimated $1.55M sold.

Candriam SCA first reported a position in STML in Q3 2016 and held it in 6 quarters. The position peaked at $2.78M in Q3 2016. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Candriam SCA reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Candriam SCA sold 149,466 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $1.55M.
Candriam SCA first reported a position in Stemline Therapeutics, Inc. in Q3 2016 and held it in 6 quarters.
Candriam SCA's Stemline Therapeutics, Inc. position peaked at $2.78M in Q3 2016.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.